Register a trial

The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT04266301




Registration number
NCT04266301
Ethics application status
Date submitted
21/01/2020
Date registered
12/02/2020

Titles & IDs
Public title
Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2)
Scientific title
A Randomized, Double-blind, Placebo-controlled Phase III Multi-center Study of Azacitidine With or Without MBG453 for the Treatment of Patients With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2)
Secondary ID [1] 0 0
2019-002089-11
Secondary ID [2] 0 0
CMBG453B12301
Universal Trial Number (UTN)
Trial acronym
STIMULUS-MDS2
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Myelodysplastic Syndromes 0 0
Leukemia, Myelomonocytic, Chronic 0 0
Condition category
Condition code
Cancer 0 0 0 0
Leukaemia - Acute leukaemia
Cancer 0 0 0 0
Leukaemia - Chronic leukaemia
Cancer 0 0 0 0
Children's - Leukaemia & Lymphoma
Blood 0 0 0 0
Haematological diseases
Blood 0 0 0 0
Other blood disorders
Other 0 0 0 0
Research that is not of generic health relevance and not applicable to specific health categories listed above

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Sabatolimab
Treatment: Drugs - Azacitidine
Treatment: Drugs - Placebo

Experimental: MBG453 (Sabatolimab) + Azacitidine - Participants will receive MBG453 plus Azacitidine

Placebo comparator: Placebo + Azacitidine - Participants will receive Placebo plus Azacitidine


Treatment: Drugs: Sabatolimab
A dose of MBG453 800 mg will be administered intravenously (IV) every 4 weeks (Q4W).

Treatment: Drugs: Azacitidine
A dose of Azacitidine 75 mg/m2 will be administered IV or subcutaneously (SC) on Day 1-7, or Day 1-5, 8 and 9.

Treatment: Drugs: Placebo
A dose of Placebo 800 mg will be administered intravenously every 4 weeks (Q4W).
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Overall Survival
Timepoint [1] 0 0
Up to 5 years after last patient randomized
Secondary outcome [1] 0 0
Key secondary endpoint 1: Time to definitive deterioration of fatigue using Functional Assessment of Cancer Therapy (FACIT)-Fatigue score
Timepoint [1] 0 0
Up to 5 years after last patient randomized
Secondary outcome [2] 0 0
Key secondary endpoint 2: Red Blood Cell transfusion-free intervals
Timepoint [2] 0 0
Up to 5 years after last patient randomized
Secondary outcome [3] 0 0
Key secondary endpoint: Percent of subjects with at least 3 point confirmed improvement from baseline in FACIT-fatigue scoresscore
Timepoint [3] 0 0
Up to 5 years after last patient randomized
Secondary outcome [4] 0 0
Key secondary endpoint 4: Percent of subjects with at least 10 point confirmed improvement from baseline in physical functioning using European Or ganization for Research and Treatment of Cancer's Core Quality of Life Questionnaire (EORTC QLQ-C30)
Timepoint [4] 0 0
Up to 5 years after last patient randomized
Secondary outcome [5] 0 0
Key secondary endpoint 5: Percent of subjects with at least 10 point confirmed improvement from baseline in emotional functioning using EORTC-QLQ-C30
Timepoint [5] 0 0
Up to 5 years after last patient randomized
Secondary outcome [6] 0 0
Percentage of subjects with either CR, or mCR, or PR, or HI in each treatment arm according to International Working Group for MDS (IWG-MDS) as per investigator assessment
Timepoint [6] 0 0
Up to 5 years after last patient randomized
Secondary outcome [7] 0 0
Percentage of subjects with SD in each treatment arm according to International Working Group for MDS (IWG-MDS) as per investigator assessment
Timepoint [7] 0 0
Up to 5 years after last patient randomized
Secondary outcome [8] 0 0
Progression Free Survival (PFS)
Timepoint [8] 0 0
Up to 5 years after last patient randomized
Secondary outcome [9] 0 0
Leukemia-free survival
Timepoint [9] 0 0
Up to 5 years after last patient randomized
Secondary outcome [10] 0 0
Number of transfusion dependent subjects at baseline who become Red Blood Cells/platelets transfusion independent after randomization
Timepoint [10] 0 0
Up to 5 years after last patient randomized as per IWG-MDS criteria
Secondary outcome [11] 0 0
Percentage of transfusion dependent subjects at baseline who become Red Blood Cells/platelets transfusion independent after randomization
Timepoint [11] 0 0
Up to 5 years after last patient randomized
Secondary outcome [12] 0 0
Pharmacokinetics of MBG453 (parameter Cmax)
Timepoint [12] 0 0
At Day 8 of each cycle (1 cycle = 28 days) until cycle 9, at day 8 of cycle 12 and every 6 cycles thereafter up to 150 day after end of study drug
Secondary outcome [13] 0 0
Pharmacokinetics of MBG453 (parameter AUC)
Timepoint [13] 0 0
At Day 8 of each cycle (1 cycle = 28 days) until cycle 9, at day 8 of cycle 12 and every 6 cycles thereafter up to 150 day after end of study drug
Secondary outcome [14] 0 0
Anti-drug Antibody (ADA) prevalence at baseline and ADA incidence on-treatment
Timepoint [14] 0 0
At Day 8 of each cycle (1 cycle = 28 days) until cycle 9, at day 8 of cycle 12 and every 6 cycles thereafter up to 150 day after end of study drug
Secondary outcome [15] 0 0
Change from baseline in the European Quality of Life (EuroQol) - 5 Dimensions, 5 Level Questionnaire (EQ-5D-5L) score over time
Timepoint [15] 0 0
Up to 5 years after last patient randomized
Secondary outcome [16] 0 0
Change from baseline in the European Quality of Life (EuroQoL) - 5 Dimensions, 5 Level Questionnaire (EQ-5D-5L) Visual Analogue Scale over time
Timepoint [16] 0 0
Up to 5 years after last patient randomized
Secondary outcome [17] 0 0
Change from baseline to C12D1 of Global Health Status/Quality of Life scores using European Organization for Research and Treatment of Cancer's Core Quality of Life Questionnaire (EORTC-QLQ-C30)
Timepoint [17] 0 0
Up to cycle 12 day 1 (C12D1)(1 cycle = 28 days)

Eligibility
Key inclusion criteria
* Signed informed consent must be obtained prior to participation in the study
* Age = 18 years at the date of signing the informed consent form
* Morphologically confirmed diagnosis of myelodysplastic syndrome (MDS) based on WHO 2016 classification (Arber et al 2016) by local investigator assessment with one of the following Prognostic Risk Categories, based on the revised International Prognostic Scoring System (IPSS-R):

* Very high (> 6 points)
* High (> 4.5 - = 6 points)
* Intermediate (> 3 - = 4.5 points) Or Morphologically confirmed diagnosis of Chronic Myelomonocytic Leukemia -2 based on WHO 2016 classification (Arber et al 2016, including persistent monocytosis) by local investigator assessment with WBC < 13 x 109/L at time of initial diagnosis
* Indication for azacitidine treatment according to the investigator, based on local standard medical practice and institutional guidelines for treatment decisions
* Not eligible at time of screening for intensive chemotherapy according to the investigator, based on local standard medical practice and institutional guidelines for treatment decisions, including assessment of individual clinical factors such as age, comorbidities and performance status
* Not eligible at time of screening for hematopoietic stem cell transplantation (HSCT) according to the investigator, based on local standard medical practice and institutional guidelines for treatment decisions, including assessment of individual clinical factors such as age, comorbidities, performance status, and donor availability
* Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Prior exposure to TIM-3 directed therapy at any time. Prior therapy with immune checkpoint inhibitors (e.g, anti-CTLA4, anti-PD-1, anti-PD-L1, or anti-PD-L2), cancer vaccines is allowed except if the drug was administered within 4 months prior to randomization
* Previous first-line treatment for intermediate, high, very high risk myelodysplastic syndromes (based on IPSS-R) or CMML with any antineoplastic agents including for example chemotherapy, lenalidomide and hypomethylating agents (HMAs) such as decitibine and azacitidine. However, previous treatment with hydroxyurea or leukopheresis to reduce WBC count is allowed prior to randomization.
* Investigational treatment received within 4 weeks or 5 half-lives of this investigational treatment, whatever is longer, prior to randomization. In case of a checkpoint inhibitor: a minimal interval of 4 months prior to randomization is necessary to allow randomization.
* Subjects with Myelodysplastic syndrome (MDS) based on 2016 WHO classification (Arber et al 2016) with revised International Prognostic Scoring System (IPSS-R) = 3
* Diagnosis of acute myeloid leukemia (AML) including acute promyelocytic leukemia and extra-medullary acute myeloid leukemia, primary or secondary myelofibrosis based on WHO 2016 classification (Arber et al 2016)
* Diagnosis of therapy related myeloid neoplasms based on WHO 2016 classification (Arber et al 2016)
* History of organ or allogeneic hematopoietic stem cell transplant

Other protocol-defined Inclusion/Exclusion Criteria may apply.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s

The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
8/06/2020
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
3/10/2024
Actual
Sample size
Target
Accrual to date
Final
530
Recruitment in Australia
Recruitment state(s)
QLD,VIC,WA
Recruitment hospital [1] 0 0
Novartis Investigative Site - Woolloongabba
Recruitment hospital [2] 0 0
Novartis Investigative Site - Clayton
Recruitment hospital [3] 0 0
Novartis Investigative Site - Perth
Recruitment postcode(s) [1] 0 0
4102 - Woolloongabba
Recruitment postcode(s) [2] 0 0
3168 - Clayton
Recruitment postcode(s) [3] 0 0
6000 - Perth
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Connecticut
Country [4] 0 0
United States of America
State/province [4] 0 0
Florida
Country [5] 0 0
United States of America
State/province [5] 0 0
Illinois
Country [6] 0 0
United States of America
State/province [6] 0 0
Massachusetts
Country [7] 0 0
United States of America
State/province [7] 0 0
New Jersey
Country [8] 0 0
United States of America
State/province [8] 0 0
New York
Country [9] 0 0
United States of America
State/province [9] 0 0
Virginia
Country [10] 0 0
Argentina
State/province [10] 0 0
Buenos Aires
Country [11] 0 0
Austria
State/province [11] 0 0
Graz
Country [12] 0 0
Austria
State/province [12] 0 0
Innsbruck
Country [13] 0 0
Austria
State/province [13] 0 0
Linz
Country [14] 0 0
Belgium
State/province [14] 0 0
Brasschaat
Country [15] 0 0
Belgium
State/province [15] 0 0
Roeselare
Country [16] 0 0
Brazil
State/province [16] 0 0
SC
Country [17] 0 0
Brazil
State/province [17] 0 0
SP
Country [18] 0 0
Canada
State/province [18] 0 0
Alberta
Country [19] 0 0
Canada
State/province [19] 0 0
Ontario
Country [20] 0 0
Chile
State/province [20] 0 0
Valparaiso
Country [21] 0 0
China
State/province [21] 0 0
Guangdong
Country [22] 0 0
China
State/province [22] 0 0
Hubei
Country [23] 0 0
China
State/province [23] 0 0
Jiangsu
Country [24] 0 0
China
State/province [24] 0 0
Jilin
Country [25] 0 0
China
State/province [25] 0 0
Zhejiang
Country [26] 0 0
China
State/province [26] 0 0
Beijing
Country [27] 0 0
China
State/province [27] 0 0
Chengdu
Country [28] 0 0
China
State/province [28] 0 0
Jinan
Country [29] 0 0
China
State/province [29] 0 0
Shanghai
Country [30] 0 0
China
State/province [30] 0 0
Tianjin
Country [31] 0 0
Colombia
State/province [31] 0 0
Antioquia
Country [32] 0 0
Colombia
State/province [32] 0 0
Bogota
Country [33] 0 0
Czechia
State/province [33] 0 0
Czech Republic
Country [34] 0 0
Czechia
State/province [34] 0 0
CZE
Country [35] 0 0
Czechia
State/province [35] 0 0
Brno - Bohunice
Country [36] 0 0
Czechia
State/province [36] 0 0
Praha
Country [37] 0 0
Finland
State/province [37] 0 0
Helsinki
Country [38] 0 0
Finland
State/province [38] 0 0
Kuopio
Country [39] 0 0
France
State/province [39] 0 0
Grenoble
Country [40] 0 0
France
State/province [40] 0 0
Lille
Country [41] 0 0
France
State/province [41] 0 0
Paris 10
Country [42] 0 0
France
State/province [42] 0 0
Toulouse
Country [43] 0 0
France
State/province [43] 0 0
Tours
Country [44] 0 0
France
State/province [44] 0 0
Vandoeuvre Les Nancy
Country [45] 0 0
Germany
State/province [45] 0 0
North Rhine-Westphalia
Country [46] 0 0
Germany
State/province [46] 0 0
Sachsen
Country [47] 0 0
Germany
State/province [47] 0 0
Augsburg
Country [48] 0 0
Germany
State/province [48] 0 0
Duesseldorf
Country [49] 0 0
Germany
State/province [49] 0 0
Frankfurt
Country [50] 0 0
Germany
State/province [50] 0 0
Greifswald
Country [51] 0 0
Germany
State/province [51] 0 0
Jena
Country [52] 0 0
Germany
State/province [52] 0 0
Kiel
Country [53] 0 0
Germany
State/province [53] 0 0
Ulm
Country [54] 0 0
Greece
State/province [54] 0 0
Evros
Country [55] 0 0
Greece
State/province [55] 0 0
Patras
Country [56] 0 0
India
State/province [56] 0 0
Gujrat
Country [57] 0 0
India
State/province [57] 0 0
Haryana
Country [58] 0 0
India
State/province [58] 0 0
TamilNadu
Country [59] 0 0
India
State/province [59] 0 0
West Bengal
Country [60] 0 0
India
State/province [60] 0 0
Delhi
Country [61] 0 0
Israel
State/province [61] 0 0
Afula
Country [62] 0 0
Israel
State/province [62] 0 0
Tel Aviv
Country [63] 0 0
Italy
State/province [63] 0 0
BO
Country [64] 0 0
Italy
State/province [64] 0 0
CT
Country [65] 0 0
Italy
State/province [65] 0 0
FI
Country [66] 0 0
Italy
State/province [66] 0 0
GE
Country [67] 0 0
Italy
State/province [67] 0 0
MI
Country [68] 0 0
Italy
State/province [68] 0 0
RC
Country [69] 0 0
Italy
State/province [69] 0 0
RM
Country [70] 0 0
Japan
State/province [70] 0 0
Aichi
Country [71] 0 0
Japan
State/province [71] 0 0
Chiba
Country [72] 0 0
Japan
State/province [72] 0 0
Fukuoka
Country [73] 0 0
Japan
State/province [73] 0 0
Hokkaido
Country [74] 0 0
Japan
State/province [74] 0 0
Kanagawa
Country [75] 0 0
Japan
State/province [75] 0 0
Miyagi
Country [76] 0 0
Japan
State/province [76] 0 0
Nagasaki
Country [77] 0 0
Japan
State/province [77] 0 0
Osaka
Country [78] 0 0
Japan
State/province [78] 0 0
Tokyo
Country [79] 0 0
Japan
State/province [79] 0 0
Yamagata
Country [80] 0 0
Korea, Republic of
State/province [80] 0 0
Seocho Gu
Country [81] 0 0
Korea, Republic of
State/province [81] 0 0
Seoul
Country [82] 0 0
Lebanon
State/province [82] 0 0
Beirut
Country [83] 0 0
Lithuania
State/province [83] 0 0
Vilnius
Country [84] 0 0
Malaysia
State/province [84] 0 0
Sarawak
Country [85] 0 0
Malaysia
State/province [85] 0 0
Kuala Lumpur
Country [86] 0 0
Malaysia
State/province [86] 0 0
Pulau Pinang
Country [87] 0 0
Malaysia
State/province [87] 0 0
Selangor
Country [88] 0 0
Mexico
State/province [88] 0 0
Distrito Federal
Country [89] 0 0
Mexico
State/province [89] 0 0
Edo Mexico
Country [90] 0 0
Mexico
State/province [90] 0 0
Michoacan
Country [91] 0 0
Mexico
State/province [91] 0 0
Estado de Mexico
Country [92] 0 0
Netherlands
State/province [92] 0 0
Groningen
Country [93] 0 0
Oman
State/province [93] 0 0
Muscat
Country [94] 0 0
Portugal
State/province [94] 0 0
Lisboa
Country [95] 0 0
Portugal
State/province [95] 0 0
Porto
Country [96] 0 0
Russian Federation
State/province [96] 0 0
Saint Petersburg
Country [97] 0 0
Russian Federation
State/province [97] 0 0
St Petersburg
Country [98] 0 0
Saudi Arabia
State/province [98] 0 0
Riyadh
Country [99] 0 0
Singapore
State/province [99] 0 0
Singapore
Country [100] 0 0
Spain
State/province [100] 0 0
Andalucia
Country [101] 0 0
Spain
State/province [101] 0 0
Asturias
Country [102] 0 0
Spain
State/province [102] 0 0
Castilla Y Leon
Country [103] 0 0
Spain
State/province [103] 0 0
Catalunya
Country [104] 0 0
Spain
State/province [104] 0 0
Comunidad Valenciana
Country [105] 0 0
Spain
State/province [105] 0 0
Madrid
Country [106] 0 0
Spain
State/province [106] 0 0
Valencia
Country [107] 0 0
Switzerland
State/province [107] 0 0
Bern
Country [108] 0 0
Switzerland
State/province [108] 0 0
Zurich
Country [109] 0 0
Taiwan
State/province [109] 0 0
Hualien
Country [110] 0 0
Taiwan
State/province [110] 0 0
Kaohsiung
Country [111] 0 0
Taiwan
State/province [111] 0 0
Liouying Township
Country [112] 0 0
Taiwan
State/province [112] 0 0
Taichung
Country [113] 0 0
Taiwan
State/province [113] 0 0
Taipei
Country [114] 0 0
Taiwan
State/province [114] 0 0
Taoyuan
Country [115] 0 0
Thailand
State/province [115] 0 0
Hat Yai
Country [116] 0 0
Thailand
State/province [116] 0 0
THA
Country [117] 0 0
Thailand
State/province [117] 0 0
Bangkok
Country [118] 0 0
Thailand
State/province [118] 0 0
Chiang Mai
Country [119] 0 0
Turkey
State/province [119] 0 0
Ankara
Country [120] 0 0
Turkey
State/province [120] 0 0
Edirne
Country [121] 0 0
Turkey
State/province [121] 0 0
Istanbul
Country [122] 0 0
Turkey
State/province [122] 0 0
Izmir
Country [123] 0 0
Turkey
State/province [123] 0 0
Samsun
Country [124] 0 0
United Kingdom
State/province [124] 0 0
Hants
Country [125] 0 0
United Kingdom
State/province [125] 0 0
Edinburgh
Country [126] 0 0
United Kingdom
State/province [126] 0 0
Manchester
Country [127] 0 0
United Kingdom
State/province [127] 0 0
Nottingham

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Novartis Pharmaceuticals
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Novartis Pharmaceuticals
Address 0 0
Novartis Pharmaceuticals
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
What data in particular will be shared?
Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent expert panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
When will data be available (start and end dates)?
Available to whom?
Available for what types of analyses?
How or where can data be obtained?


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.


Results not provided in https://clinicaltrials.gov/study/NCT04266301